Search clinical trials for: LAF237 (vildagliptin)

Total 194 results

Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride (GLOBE)

Hypoglycemia | Type 2 Diabetes

Colombia
Reseach Laboratory of Clinical and Experimental...
Société Arabe des Industries Pharmaceutiques SAIPH - Tunisia; Centre National...

Completed

Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®

Fed Conditions

Tunisia
Damanhour University

Recruiting

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Type 2 Diabetes

Egypt
Beni-Suef University
Minia University

Completed

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Egypt
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Novartis

Completed

A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.

Diabetes Mellitus, Type 2

Germany
Novartis Pharmaceuticals

Completed

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novartis

Completed

Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis

Completed

A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

United Kingdom, Belgium, Bulgaria, Spain, Slovakia, Germany, Finland
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Diabetes | Renal Impairment

Russian Federation
University of Zurich

Unknown

The Swiss Glucose Variability Study

Type 2 Diabetes

Switzerland
Novartis

Completed

Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis

Completed

To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis

Completed

To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy

Diabetes Mellitus, Type 2

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine
Damanhour University
Tanta University

Completed

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Coronary Artery Disease | Diabetes Mellitus, Type 2

Egypt
Novartis

Completed

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Philippines, India, Puerto Rico, Canada, Malaysia, Romania, Slovakia
India Diabetes Research Foundation & Dr. A. Ramachandran...

Completed

A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

TYpe 2 Diabetes Mellitus

India
Royal Devon and Exeter NHS Foundation Trust
Novartis Pharmaceuticals; National Institute for Health Research, United Kingdom

Completed

The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

Insulin Resistance | Microvascular Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United Kingdom
Novartis

Completed

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

Diabetes Mellitus, Type 2
MTI University
National Institute of Diabetes and Endocrinology, Egypt

Recruiting

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Egypt
University Malaysia Sarawak
Sarawak General Hospital

Completed

DPP4 Inhibitor on Glycemic Variability

Diabetes Mellitus, Type 2

Malaysia
Novartis

Completed

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Medical University of Vienna

Completed

Vildagliptin in New Onset Diabetes After Transplantation (VINODAT)

Diabetes Mellitus

Austria
Novartis

Completed

Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

Healthy | Type-2 Diabetes

Germany
University Hospital, Toulouse
Novartis Pharmaceuticals; Institute of Molecular Medicine of Rangueil (I2MR); Faculty of Medicine, Toulouse

Completed

Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy (DPPNAC)

Diabetes Mellitus

France
Johann Wolfgang Goethe University Hospital

Withdrawn

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM). (FINNjA-DM)

SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors

Germany
Novartis Pharmaceuticals

Completed

Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Novartis

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, Romania, Hungary, Belgium, Slovakia, Australia, India, Czech Republic, Guatemala, Hong Kong, United Kingdom
Sadat City University

Active, not recruiting

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Major Depressive Disorder

Egypt
Novartis

Completed

Phase 4 Study in the Elderly Patients With T2DM (GLYCEMIA)

Type 2 Diabetes Mellitus | Elderly

France
Novartis

Completed

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Pre-diabetes

United States
Merck Sharp & Dohme LLC

Completed

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Type 2 Diabetes Mellitus
University of Jordan

Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Diabetes Mellitus, Type 2

Jordan
Imperial College London

Active, not recruiting

Noradrenergic Add-on Therapy With Guanfacine (NorAD)

Alzheimer Disease

United Kingdom
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Healthy

Egypt
Centre Hospitalier Universitaire de Besancon
University Hospital, Strasbourg, France; Centre Hospitalier Universitaire de... and other collaborators

Recruiting

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (PRODIG)

Diabetes | Disorder Related to Renal Transplantation

France
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Diabetes Mellitus, Type 2

Spain, Argentina, Russian Federation, Norway, India, Sweden, Finland, France, Canada, Germany, Australia, Costa Rica
Novartis

Completed

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis Pharmaceuticals

Terminated

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes (VIDA)

Type 2 Diabetes Mellitus

Mexico
Lund University

Completed

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Hypoglycemia | Diabetes

Sweden
SatRx LLC

Completed

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Diabetes Mellitus, Type 2

Russian Federation
Novartis

Completed

Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride (Vildagliptin)

Type 2 Diabetes Mellitus

Taiwan, Philippines, Italy, Germany, Romania, Hungary, Australia, Korea, Republic of, Mexico
Federal University of São Paulo
Novartis

Unknown

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

Type 1 Diabetes | Autoimmune Diabetes | Insulin Dependent Diabetes | Juvenile Onset Diabetes Mellitus

Brazil
Marcus Saemann

Completed

Glucose Control in Pre-Diabetic Renal Transplant Patients (GCPD)

Kidney Transplantation | Impaired Glucose Tolerance

Austria

3

Subscribe